A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705 · clinicaltrials.gov ↗

RECRUITING

Status

1600

Enrollment

INDUSTRY

Sponsor class

Conditions

Obstructive Hypertrophic Cardiomyopathy

Interventions

DRUG: Mavacamten
DRUG: Non-mavacamten symptomatic oHCM therapy

Sponsor

Bristol-Myers Squibb